Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Comparable outcomes in patients aged ≥70 vs. 70 undergoing allogeneic transplantation with fludarabine and melphalan conditioning and post-transplant cyclophosphamide

View Full Paper
Ask AI
Bookmark
Share

Authors

ACAndy ChenRCRachel C. CookJLJessica T. Leonard

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows similar outcomes for graft-versus-host disease in older and younger patients receiving hematopoietic cell transplant with melphalan conditioning.

Key Points

  • This research aims to compare survival outcomes and graft-versus-host disease rates in patients aged ≥70 and <70 undergoing allogeneic transplantation with melphalan conditioning.
  • Retrospective single-center study at Oregon Health & Science University
  • Compared disease response, toxicity, and graft-versus-host disease outcomes in two age groups
  • Utilized various survival outcome measures including overall survival and relapse-free survival
  • 1-year overall survival was 88.2% for <70 and 92.0% for ≥70, not significantly different (p=0.0785)
  • Similar incidence rates of acute graft-versus-host disease between groups (p=0.3012)
  • Median length of hospital stay was identical at 22 days for both age groups

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8bdhttps://doi.org/10.1182/blood-2025-6085
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxis2025
  2. 2Outcomes after unrelated donor allogeneic hematopoietic cell transplantation in age ≥65 using post-transplant cyclophosphamide.2026
  3. 3Allograft for myeloid malignancies in the year of 70 years old and beyond: No impact of pre-graft immune, nutritional and inflammatory status on outcome.2025
  4. 4Superior long-term outcomes with fludarabine and melphalan reduced intensity regimen in older AML/MDS patients undergoing allogeneic stem cell transplantation: An analysis of CIBMTR data2025 · 1 citations
  5. 5Outcomes and associated factors after melphalan 140 mg/m² autologous hematopoietic cell transplantation for multiple myeloma in patients over 70 years of age2025